Cogent Biosciences Quarterly Balance Sheet
NASDAQ: COGTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Cogent Biosciences financial position
As of Jun 30, 2026, Cogent Biosciences reported total assets of $834.5 million, up 203.7% from a year earlier against total liabilities of $302.2 million. Shareholders' equity stood at $532.4 million, or 63.8% of assets. The company held $181.2 million in cash and equivalents against $223.5 million of debt, a net debt position of $42.3 million.
The current ratio (current assets divided by current liabilities) was 13.57, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.42.
Summary generated from market data by MetaCap's automated system. Methodology
Cogent Biosciences balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 181.17M | 241.21M | 312.01M | 125.30M | 127.60M | 126.00M | 98.17M | 97.05M | 88.22M | 215.80M | 53.23M | 86.81M |
| Short-Term Investments | 611.13M | 625.17M | 588.75M | 265.59M | 110.25M | 119.66M | 188.91M | 238.47M | 275.00M | 219.94M | 212.48M | 192.23M |
| Total Current Assets | 804.82M | 877.80M | 910.36M | 397.24M | 245.01M | 252.88M | 296.47M | 341.53M | 369.97M | 441.90M | 270.77M | 285.95M |
| Property, Plant & Equipment | 4.78M | 5.30M | 5.46M | 5.27M | 5.85M | 6.45M | 6.47M | 7.02M | 7.36M | 7.82M | 8.34M | 8.64M |
| Long-Term Investments | — | — | — | — | — | — | — | 10.03M | 26.69M | 0 | 7.46M | 33.79M |
| Total Assets | 834.55M | 903.01M | 937.61M | 425.93M | 274.82M | 283.80M | 327.90M | 384.02M | 429.94M | 476.11M | 313.44M | 355.45M |
| Accounts Payable | 7.49M | 13.74M | 9.50M | 16.03M | 16.63M | 14.15M | 12.01M | 15.06M | 8.97M | 15.56M | 10.65M | 9.87M |
| Total Current Liabilities | 59.30M | 57.98M | 63.95M | 62.25M | 58.42M | 49.32M | 55.71M | 53.05M | 40.00M | 36.69M | 38.17M | 34.72M |
| Long-Term Debt | 223.46M | 223.17M | 222.90M | 44.25M | 43.95M | — | 0 | — | — | — | — | — |
| Total Liabilities | 302.16M | 295.31M | 301.24M | 123.47M | 119.78M | 64.80M | 71.61M | 69.36M | 56.71M | 53.78M | 55.63M | 52.55M |
| Shareholders' Equity | 532.39M | 607.69M | 636.37M | 302.46M | 155.04M | 219.00M | 256.29M | 314.66M | 373.22M | 422.33M | 257.80M | 302.90M |
| Retained Earnings | -1.38B | -1.29B | -1.19B | -1.09B | -1.00B | -931.47M | -859.48M | -791.56M | -720.92M | -661.97M | -603.62M | -549.26M |
| Total Debt | 223.46M | 223.17M | 222.90M | 44.25M | 43.95M | — | 0 | — | — | — | — | — |
| Net Cash (Debt) | 568.84M | 643.21M | 677.87M | 346.64M | 193.90M | 245.66M | 287.08M | 335.52M | 363.22M | 435.74M | 265.71M | 279.04M |
| Shares Outstanding | 171.60M | 170.77M | 160.98M | 139.83M | 113.93M | 113.86M | 110.46M | 110.46M | 109.34M | 95.61M | 86.12M | 86.12M |
This table shows 12 quarterly periods of Cogent Biosciences's balance sheet, from Q2 2026 back to Q3 2023, across 16 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow COGT's reporting calendar. What is a balance sheet?